Cara Therapeutics Inc (NASDAQ:CARA) Director Sells $64,575.00 in Stock

Cara Therapeutics Inc (NASDAQ:CARA) Director Jeffrey L. Ives sold 2,500 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $25.83, for a total transaction of $64,575.00. Following the transaction, the director now directly owns 8,500 shares in the company, valued at $219,555. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of Cara Therapeutics stock opened at $16.76 on Friday. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $670.67 million, a P/E ratio of -8.13 and a beta of 2.30. The business has a fifty day simple moving average of $21.33 and a two-hundred day simple moving average of $21.58. Cara Therapeutics Inc has a 12 month low of $12.19 and a 12 month high of $27.55.

Cara Therapeutics (NASDAQ:CARA) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.15). The business had revenue of $5.79 million during the quarter, compared to analysts’ expectations of $5.56 million. Cara Therapeutics had a negative return on equity of 70.35% and a negative net margin of 470.70%. Analysts predict that Cara Therapeutics Inc will post -2.55 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of CARA. Commonwealth Equity Services LLC boosted its stake in Cara Therapeutics by 5.9% during the second quarter. Commonwealth Equity Services LLC now owns 14,557 shares of the biopharmaceutical company’s stock worth $312,000 after acquiring an additional 814 shares in the last quarter. California Public Employees Retirement System grew its holdings in Cara Therapeutics by 16.6% in the third quarter. California Public Employees Retirement System now owns 99,851 shares of the biopharmaceutical company’s stock worth $1,825,000 after purchasing an additional 14,248 shares during the period. LPL Financial LLC increased its stake in shares of Cara Therapeutics by 6.2% during the second quarter. LPL Financial LLC now owns 136,972 shares of the biopharmaceutical company’s stock valued at $2,945,000 after purchasing an additional 7,960 shares in the last quarter. ETF Managers Group LLC bought a new position in shares of Cara Therapeutics during the second quarter valued at approximately $20,490,000. Finally, Farallon Capital Management LLC purchased a new position in shares of Cara Therapeutics during the second quarter valued at approximately $20,454,000. 76.08% of the stock is owned by institutional investors.

Several equities research analysts have recently commented on the stock. BidaskClub raised shares of Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Cantor Fitzgerald boosted their price target on shares of Cara Therapeutics from $29.00 to $33.00 in a research report on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $35.00 price target on shares of Cara Therapeutics in a research note on Tuesday. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Cara Therapeutics in a research note on Tuesday. Finally, Zacks Investment Research lowered shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. Cara Therapeutics has a consensus rating of “Buy” and an average price target of $27.54.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Featured Article: Understanding Specialty Certificates of Deposit

Insider Buying and Selling by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.